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individuals (40 females and 115 males) were first diagnosed with OSA. Among these 155 patients, 34% had
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and neither major symptom as asymptomatic (40%). There were no significant statistical differences
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patients expressed anxiety and depression more often than asymptomatics (p lt; 0.001) and had poorer
subjective sleep quality (Gr-PSQI, p lt; 0.001). According to PSQI questionnaire, there were no SSDs
regarding hours in bed and the use of sleep medications, but there were significant differences in the
subjective perception of sleep quality (p lt; 0.001), sleep efficiency (p lt; 0.001), duration of sleep (p
= 0.001), sleep latency (p = 0.007), daytime dysfunction (p lt; 0.001), and finally sleep disturbances
(p lt; 0.001).Conclusion: According to our data, OSA patients reporting insomnia-like symptoms and/or
sleepiness do not represent a more severe phenotype, by the classic definition of OSA, but their subjective
sleep quality is compromised, causing a vicious cycle of anxiety or depression.
DOI: https://doi.org/10.3389/fpsyt.2021.630162






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Frangopoulos, Frangiskos; Zannetos, Savvas; Nicolaou, Ivi; Economou, Nicholas-Tiberio; Adamide, Tonia;
Georgiou, Andreas; Nikolaidis, Pantelis T; Rosemann, Thomas; Knechtle, Beat; Trakada, Georgia (2021).
The Complex Interaction Between the Major Sleep Symptoms, the Severity of Obstructive Sleep Apnea,




published: 25 February 2021
doi: 10.3389/fpsyt.2021.630162







University of Palermo, Italy
Frederic Roche,





This article was submitted to
Sleep Disorders,
a section of the journal
Frontiers in Psychiatry
Received: 17 November 2020
Accepted: 29 January 2021
Published: 25 February 2021
Citation:
Frangopoulos F, Zannetos S,
Nicolaou I, Economou N-T,
Adamide T, Georgiou A, Nikolaidis PT,
Rosemann T, Knechtle B and
Trakada G (2021) The Complex
Interaction Between the Major Sleep
Symptoms, the Severity of Obstructive
Sleep Apnea, and Sleep Quality.
Front. Psychiatry 12:630162.
doi: 10.3389/fpsyt.2021.630162
The Complex Interaction Between
the Major Sleep Symptoms, the
Severity of Obstructive Sleep Apnea,
and Sleep Quality
Frangiskos Frangopoulos 1, Savvas Zannetos 2, Ivi Nicolaou 1,
Nicholas-Tiberio Economou 3, Tonia Adamide 1, Andreas Georgiou 1, Pantelis T. Nikolaidis 4,
Thomas Rosemann 5, Beat Knechtle 5 and Georgia Trakada 3*
1 Respiratory Department, Nicosia General Hospital, Nicosia, Cyprus, 2Health Economics and Statistics, Neapolis University,
Paphos, Cyprus, 3Division of Pulmonology, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital,
National and Kapodistrian University of Athens, Athens, Greece, 4 School of Health and Caring Sciences, University of West
Attica, Athens, Greece, 5 Institute of Primary Care, University of Zurich, Zurich, Switzerland
Introduction: Little information exists in the general population whether clinical
presentation phenotypes of obstructive sleep apnea (OSA) differ in terms of sleep quality
and comorbidities.
Aim: The purpose of our study was to assess possible differences between symptomatic
and asymptomatic OSA patients concerning syndrome’s severity, patients’ sleep quality,
and comorbidities.
Subjects and methods: First, in a nationwide, stratified, epidemiological survey, 4,118
Cypriot adult participants were interviewed about sleep habits and complaints. In the
second stage of the survey, 264 randomly selected adults underwent a type III sleep
study for possible OSA. Additionally, they completed the Greek version of Pittsburgh
Sleep Quality Index (Gr-PSQI), Epworth Sleepiness Scale (ESS), Athens Insomnia Scale
(AIS), and Hospital Anxiety and Depression Scale (HADS).
Results: From 264 enrolled participants, 155 individuals (40 females and 115 males)
were first diagnosed with OSA. Among these 155 patients, 34% had ESS ≥ 10 and
49% AIS ≥ 6. One or both symptoms present categorized the individual as symptomatic
(60%) and neither major symptom as asymptomatic (40%). There were no significant
statistical differences (SSDs) between the two groups (symptomatic–asymptomatic) with
regard to anthropometrics [age or gender; neck, abdomen, and hip circumferences;
and body mass index (BMI)]. The two groups had no differences in OSA severity—as
expressed by apnea–hypopnea index (AHI), oxygen desaturation index (ODI), and mean
oxyhemoglobin saturation (SaO2)—and in cardiometabolic comorbidities. Symptomatic
patients expressed anxiety and depression more often than asymptomatics (p < 0.001)
and had poorer subjective sleep quality (Gr-PSQI, p < 0.001). According to PSQI
questionnaire, there were no SSDs regarding hours in bed and the use of sleep
medications, but there were significant differences in the subjective perception of sleep
quality (p < 0.001), sleep efficiency (p < 0.001), duration of sleep (p = 0.001), sleep
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latency (p = 0.007), daytime dysfunction (p < 0.001), and finally sleep disturbances
(p < 0.001).
Conclusion: According to our data, OSA patients reporting insomnia-like symptoms
and/or sleepiness do not represent a more severe phenotype, by the classic definition of
OSA, but their subjective sleep quality is compromised, causing a vicious cycle of anxiety
or depression.
Keywords: obstructive sleep apnoea, sleep quality, anxiety, depression, cardiometabolic comorbidities
INTRODUCTION
Obstructive sleep apnea (OSA) is defined as a disorder of sleep
presenting repetitive (either complete or partial) closure of the
upper airway. These apneas and hypopneas lead to oxygen
desaturation, activation of the autonomous nervous system,
and micro arousals. OSA is related with increased morbidity
and mortality, and literature indicates an association among
OSA, hypertension, cardiovascular disease (CVD), and insulin
resistance (1). OSA is a very common disorder with a great
additive impact on public health. Epidemiologic data in Northern
Europe estimate the prevalence of moderate and severe OSA to
23.4% in women and 49.7% in men (2). A recent epidemiologic
study in the general population of Cyprus approximates the
intermediate-to-high risk for OSA prevalence to be 50% in
males and 18% in females (3). The increase of reported OSA
prevalence over time is attributed to the obesity epidemic,
the advanced polysomnographic recording techniques, and the
revision of the diagnostic criteria (4). In a South American
population-based epidemiologic study, 32.8% of the participants
had OSA and 16.9% had an apnea–hypopnea index (AHI)
≥ 15. In the same study, Epworth Sleepiness Scale (ESS) >
9 and/or frequencies higher than once a week of the eighth
question of Pittsburgh Sleep Quality Index (PSQI) classified the
participants in the 55% of the population experiencing sleepiness
(5). A study in Spain recorded hypersomnolence in 18% of
the subjects and was not related with OSA (6). Interestingly, a
longitudinal study of the Wisconsin Sleep Cohort estimated a
3-fold greater mortality risk for participants with severe sleep-
disordered breathing (SDB), independently of sleepiness (7). In
a large cluster analysis, depression was the lowest (5.2%) in the
group with young overweight, minimally symptomatic without
comorbidities group and greater (26.4%) in the middle-aged
symptomatic multimorbid OSA group (8). Even less evidences
exist in the literature concerning insomnia and OSA, as initially it
was not considered a symptom related to OSA.What could be the
clinical importance of daytime symptoms is yet to be answered.
Several screening questionnaires have been validated to
identify patients with OSA, based mainly on symptoms and
demographics data. Patients often complain about sleepiness
and/or insomnia-like symptoms. There is considerable variability
in symptom perception and expression, biological severity, and
consequences of the syndrome and sleep quality among patients,
even though OSA diagnosis is usually defined by AHI.
Recent studies have suggested that this heterogeneity of OSA
could be due to different phenotypes in terms of symptoms
and have aimed to identify clinical subtypes of OSA, taking
into account demographics, severity of disease, symptoms, and
comorbidities (9–12). A pioneer study identified three groups:
(a) disturbed sleep (insomnia and restless sleep), (b) minimally
symptomatic, and (c) excessive sleepiness during daytime
(9). Consequent studies identified similar or more specific-
oriented groups. For example, a multicenter study described
five clinical phenotypes: (a) disturbed sleep, (b) minimally
symptomatic, (c) upper airway symptoms with sleepiness, (d)
upper airway symptoms dominant, and (e) sleepiness dominant
(with few other symptoms) (10). A prospective longitudinal
study of adult patients with OSA (AHI of ≥5/h) examined four
clinical presentation phenotypes considering daytime symptoms
described as excessive daytime sleepiness (EDS) and nocturnal
sleep problems other than OSA (insomnia): (1) EDS, (2)
EDS/insomnia, (3) non-EDS/non-insomnia, (4) and insomnia
phenotype (11). In another attempt to investigate treatment
outcomes on different clinical phenotypes, a study identified five
distinct clusters with marked clinical differences (12). Sleepiness,
insomnia, and lack of symptoms are the common components of
all taxonomy efforts.
Multiple subcategorizations, though interesting, minimally
improve our diagnostic abilities, treatment options, progression
of the syndrome, and outcome prediction. Our attempt was
to investigate potential differences between two main groups:
those expressing major symptoms (sleepiness and/or insomnia)
and those with minimal symptoms. The latent is a silent group,
difficult to identify during screening and with potentially the
same harmful consequences of OSA. We designed this study in
order to assess possible differences between symptomatic and
asymptomatic patients, concerning the severity of the syndrome,
the prevalence of comorbidities, the subjective sleep quality, and
common mental disturbances, namely, anxiety and depression.
SUBJECTS AND METHOD
In a large-scale epidemiologic study conducted in the adult
general population, 4,118 adult participants were interviewed
in order to estimate OSA prevalence in Cyprus [Cyprus Sleep
Apnea Epidemiological Study (CySAES)] (3). The initial sample
consisted of adult individuals residing in Cyprus. Inclusion
criteria were (1) age ≥ 18 years, (2) Cypriot citizens, and (3)
consent to participate in the study. The sample was categorized
based on the last demographic report (2016) by district, rural,
or urban area; gender; and age (13). The questionnaire was
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FIGURE 1 | Study selection flowchart.
administered using computer-assisted telephone interviewing
(CATI) method (14). First, all eligible participants were
interviewed by phone and answered a modified STOP-Bang
questionnaire in order to estimate OSA risk. A secondary cross-
sectional nationwide survey was piloted to examine the validity
of the estimated screening results. From the initial representative
sample, 344 adults were randomly selected to participate in the
second stage procedure by undertaking a type III sleep study.
A type III sleep testing device monitors a minimum of four
channels that include one or more channels of respiratory effort,
airflow, oxygen saturation, and heart rate/electrocardiogram. No
strict inclusion or exclusion criteria were applied in this second
phase of the study, in order to guarantee no bias in the selection,
minimize the necessary sample size, and achieve reliable results.
Participants were excluded from the analyses only if they had
a previous known history of sleep apnea and/or were under
treatment with continuous positive airway pressure (CPAP)
or other therapies. The flowchart of the study is summarized
in Figure 1.
A total of 264 adults (76.74%, age: 21–83 years) finally
underwent a type III sleep study assessment for possible OSA.
Standards from the American Academy of Sleep Medicine
(AASM) manual were used to score respiratory events (15).
The AHI was calculated as the mean number of apneas and
hypopneas per hour of sleep study. AHI ≥ 5 was considered
diagnostic for sleep apnea regardless of symptoms.
Additionally, all subjects provided a self-reported medical
history about previously diagnosed comorbidities (hypertension,
arrhythmias, heart failure, ischemic heart disease, previous
stroke, and diabetes mellitus) and answered the Greek version of
PSQI (Gr-PSQI), ESS, Athens Insomnia Scale (AIS), andHospital
Anxiety and Depression Scale (HADS).
PSQI questionnaire contains 19 self-rated questions and 5
questions rated by the bed partner or roommate. Only self-rated
questions are included in the scoring. The 19 self-rated questions
are combined to form 7 component scores; each one has a range
of 0–3 points and represents 7 clinically derived domains of sleep
difficulties. In all cases, 0 indicates no difficulty, while 3 indicates
severe difficulty. The seven component scores are then summed
to yield total surrogate PSQI score (global PSQI) with a range
of 0–21 points, with 21 indicating severe difficulties in all areas
(16). Self-administered score of >5 has a diagnostic sensitivity
of 89.6% and specificity of 86.5% to distinguish “poor” sleepers
from “good” sleepers, even though it is not related to objective
sleep measures [actigraphy and polysomnography (PSG)] in a
community sample.
ESS measures the general level of sleepiness by asking people
to rate their usual chances of dozing off or falling asleep
in eight different situations or activities of their daily lives.
Although a score > 10 is considered affirmative for excessive,
self-rated, daytime sleepiness, the correlation between ESS and
mean sleep latency or measures of sleep apnea severity is
low (17).
AIS is designed to assess the nature, severity, and impact of
insomnia and monitor treatment response in adults. A cutoff
score of ≥6 is used to establish the diagnosis of insomnia
(18). The eradication of primary and secondary definitions of
insomnia allows the clinicians to diagnose insomnia regardless
of the causes of the disorder.
Finally, HADS is a reliable instrument for detecting and
separating the states of depression and anxiety, by excluding
somatic symptoms (19). Scores of >10 are indicative of
psychological morbidity, whereas scores between 8 and 10 are
considered borderline.
Known psychiatric pathologies were ruled out at the
time of inclusion, by using a self-reported medical history
table describing the major psychiatric and neurologic
pathologies and medication that could affect the scores of
the symptom questionnaires.
We divided newly diagnosed sleep apneic patients in
symptomatics (Group A) and asymptomatics (Group B)
in order to investigate possible differences between the
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TABLE 1 | Characteristics of the SDB group participants.
Gender 1 =
female 2 = male
Age BMI ESS AIS PSQI HADS-Anxiety HADS-Depression AHI
2 78 31.9 4 0 4 1 2 13.2
2 65 35.8 7 15 14 8 11 45.3
2 64 28.9 2 4 5 1 3 22
2 81 23.1 1 3 5 7 5 13.3
2 57 27.4 0 0 5 1 2 20.4
2 36 30.8 10 9 7 6 8 33.2
1 58 29.5 11 7 4 4 7 38.8
2 48 30.0 9 8 4 4 7 9.4
2 69 33.3 2 3 1 7 6 18.6
1 54 29.4 8 4 5 5 2 14.1
1 63 25.0 6 4 9 3 6 6.2
1 65 34.2 4 5 6 4 1 40.1
2 66 27.0 2 1 7 2 9 86
2 65 24.0 17 2 2 6 2 14.3
1 60 29.7 3 9 6 5 5 10.5
2 55 28.7 11 4 7 6 6 30.1
1 72 32.4 4 6 6 2 2 28.9
1 67 25.2 5 3 5 7 8 28.8
1 87 45.0 10 17 7 9 6 14
2 69 35.2 2 1 3 0 0 19.4
2 66 35.2 13 6 4 3 6 42.9
1 44 24.8 10 5 5 1 0 5.1
1 64 21.3 17 2 5 1 2 30.5
2 39 28.1 8 4 7 6 5 15.4
2 52 45.0 10 10 7 6 9 58.6
2 33 25.8 7 1 5 2 0 15.6
2 67 27.4 5 6 5 5 8 6.2
2 49 28.4 5 7 6 6 2 16.1
2 53 30.9 9 7 4 3 5 14.7
2 58 24.8 5 8 9 1 1 7.7
1 54 34.4 15 5 10 7 7 24.5
2 46 25.2 7 5 4 3 5 8.9
2 59 32.5 12 11 14 14 8 13.3
2 58 40.5 6 13 9 9 13 48.2
1 65 25.4 4 4 3 4 1 1.6
2 81 22.9 2 4 6 3 1 13.3
1 68 29.7 8 20 6 16 11 7.9
2 68 38.6 14 11 13 1 6 34.4
2 72 24.2 11 4 4 6 7 15.7
2 42 34.5 19 10 18 18 17 9.3
2 43 32.6 8 10 6 0 9.8
1 36 40.3 15 14 13 15 12 27.5
1 51 30.5 17 6 8 13 7 30
1 65 36.7 7 5 2 8 4 11.5
2 71 38.8 8 7 2 0 0 40.1
2 69 23.5 2 2 2 4 13 6.4
2 58 27.5 10 1 7 10 9 7.9
1 55 44.8 21 14 13 2 2 13.2
2 66 23.7 3 4 5 6 7 10.6
2 72 38.0 16 14 9 6 11 22.1
2 63 35.2 9 17 13 10 5 36.8
(Continued)
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TABLE 1 | Continued
Gender 1 =
female 2 = male
Age BMI ESS AIS PSQI HADS-Anxiety HADS-Depression AHI
2 60 37.2 8 1 4 3 5 9.2
2 23 34.9 4 10 8 1 4 6.4
2 56 30.3 12 9 9 1 1 14
2 43 36.1 14 1 5 1 0 8.9
2 59 32.1 2 2 6 1 0 22.8
2 75 28.4 14 11 11 12 10 7.3
2 69 30.6 2 4 6 2 2 23.1
2 49 24.1 19 5 3 4 7 5.4
2 49 27.4 2 6 6 3 5 14.2
2 51 27.2 12 12 11 9 9 8
2 46 24.7 2 2 4 3 1 6.5
1 54 36.6 5 4 3 1 7 82
2 39 26.6 9 5 4 5 2 7.2
2 68 28.3 12 10 10 5 3 44.8
2 51 27.2 17 8 8 13 9 8
2 40 31.7 6 8 7 9 10 10.9
2 57 31.9 3 2 2 1 2 23.4
2 51 33.2 16 18 13 9 8 26
1 59 32.0 18 11 7 12 8 26.7
2 24 37.2 12 12 13 12 7 9.5
2 48 23.4 7 5 5 8 4 7.6
2 76 27.4 6 5 4 2 4 14.7
2 57 29.8 7 5 8 3 1 18.8
1 49 26.8 8 9 7 9 9 5.5
2 71 30.4 2 2 2 1 0 48.1
2 33 25.2 17 15 15 4 3 9.8
2 78 24.5 0 3 4 2 0 22.6
2 34 24.8 11 5 4 6 1 8.2
2 51 21.3 8 14 13 6 2 14.9
1 50 32.0 8 4 10 4 4 10
2 73 34.9 8 9 9 1 1 27.1
1 51 38.6 17 15 11 8 6 78.7
2 37 27.8 5 10 5 7 5 32.7
1 60 33.0 6 4 7 4 2 13
1 39 23.1 5 17 7 3 3 7.9
1 64 37.2 4 6 9 14 7 10.1
1 62 24.0 15 10 10 2 6 24.6
2 38 33.9 13 2 4 1 1 5.3
2 77 32.6 14 16 16 11 13 20.8
2 51 25.3 7 3 5 1 3 8.4
1 61 33.3 0 3 5 3 2 10.4
2 71 36.3 14 7 12 3 8 44.6
1 59 24.1 20 8 7 10 10 12.5
2 56 33.8 9 13 13 8 8 9.1
2 63 28.4 8 0 3 0 0 30.7
2 44 25.0 13 16 13 3 4 13.6
2 57 28.7 14 9 13 8 2 10.5
2 46 29.1 5 10 5 9 11 11.1
2 72 19.9 8 13 17 9 9 15.3
2 53 25.5 2 0 1 0 0 5.6
2 59 26.0 12 9 7 11 9 17.8
(Continued)
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TABLE 1 | Continued
Gender 1 =
female 2 = male
Age BMI ESS AIS PSQI HADS-Anxiety HADS-Depression AHI
2 68 33.4 4 5 4 1 1 13.6
1 56 35.6 5 10 7 8 5 7.7
2 50 25.3 8 11 7 8 4 11.4
1 61 32.4 2 5 5 8 5 12.2
2 61 26.1 20 8 6 6 0 11.7
1 77 34.7 7 4 11 0 1 33.3
2 76 24.6 1 3 4 6 5 7.6
2 54 30.4 5 1 3 0 0 17.1
1 64 33.3 4 10 12 12 5 11.9
2 47 25.9 13 7 4 3 9 11.3
2 78 31.2 1 7 7 2 2 11.2
2 21 35.6 8 3 3 3 5 15.3
2 60 21.6 5 2 3 6 8 39.3
2 68 32.2 4 3 3 1 10.3
1 54 22.7 15 3 4 9 5 10.7
2 57 36.1 9 3 8 10 5 62.8
1 54 23.7 2 1 4 5 2 5.4
2 58 32.1 18 12 11 8 11 47.1
2 74 22.8 5 3 5 3 6 15.5
2 37 27.1 11 3 4 0 4 10.1
1 55 20.4 13 9 15 10 9 13.1
2 73 30.5 8 16 16 9 8 9.2
2 69 29.8 6 15 11 6 5 18.7
2 59 25.2 9 5 6 7 3 42.5
2 59 26.4 5 5 4 2 2 19.1
2 64 29.6 4 2 5 3 4 48.4
2 52 30.7 11 10 6 1 1 31.5
2 65 24.8 3 6 3 1 1 8.4
2 50 20.7 6 5 4 6 1 5.8
2 71 28.7 6 6 9 5 9.6
2 69 26.0 9 8 12 15 13 7.4
1 73 29.7 0 6 15 2 2 7.3
2 59 36.0 13 0 0 8 2 7.6
2 32 31.1 2 1 4 3 0 11.7
2 55 26.1 2 9 10 5 7 18
1 69 23.6 5 0 4 0 0 32.8
2 37 25.4 8 2 1 4 0 7
2 52 28.7 10 1 3 2 2 6.5
2 47 25.8 5 5 7 5 1 9.6
2 39 39.4 4 6 2 3 0 5.3
2 48 23.1 4 1 5 3 1 13.3
2 68 30.5 17 3 2 0 0 17.6
2 57 32.6 15 1 2 0 0 33
2 34 25.7 9 9 6 12 9 5.5
1 60 37.0 4 9 19 6 4 13.9
2 57 47.2 2 0 3 0 0 30.3
2 59 21.2 1 2 4 3 5 9.7
1 42 35.4 3 4 3 6 5 39.8
1 49 28.2 10 15 11 13 10 14.4
2 47 37.2 4 7 3 2 5 28.1
(Continued)
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TABLE 1 | Continued
Gender 1 =
female 2 = male
Age BMI ESS AIS PSQI HADS-Anxiety HADS-Depression AHI
2 60 40.4 12 6 5 3 3 12.5
2 53 31.1 3 4 5 15 18 8.9
1 74 26.8 7 9 10 6 10 49.7
SDB, sleep-disordered breathing; BMI, body mass index; ESS, Epworth Sleepiness Scale; AIS, Athens Insomnia Scale; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety
and Depression Scale; AHI, apnea–hypopnea index.







Sex, male (%) 72.9 74.35
Age (years) 55.78 ± 12.5 59.29 ± 12.77
Neck circumference
(cm)
42.30 ± 4.22 41.76 ± 4.27
Hip circumference (cm) 112.8 ± 10.77 110.74 ± 10.95
Abdomen
circumference (cm)
107.6 ± 15.83 104.64 ± 14.15
Body mass index
(kg/m2 )
30.69 ± 5.64 28.94 ± 5.09
two groups concerning syndrome’s severity, patients’ sleep
quality, and comorbidities. One or both symptoms (sleepiness
and/or insomnia-like) present categorized the individual as
symptomatic (93 individuals, 60%) and neither major symptom
as asymptomatic (62 individuals, 40%).
The study protocol was approved by the Institutional Review
Board of both the General Hospital in Nicosia, Cyprus, and
the “Alexandra” University Hospital in Greece, and the Cyprus
Bioethics Committee (EEBK/EP/2016/35). All subjects gave
consent to participate in the study after appropriate information
was given.
Statistical analysis included summarization of the data
in tables and charts, and it was performed by using a
statistical analysis software platform (IBM SPSS Statistics
v.25 program). Specifically, χ2 test was performed when
comparing nominal variables, and t-tests were performed
when comparing continuous variables. Continuous variables
are summarized with means and standard deviations and
compared using t-tests. Categorical variables are summarized
using frequencies and percentages and compared among
groups using chi-squared. Descriptive statistics procedures
for complex survey data (chi-square) were used to examine
demographic and health characteristics for all participants.
Two-sided hypothesis testing was performed in order to
reject or not the null hypothesis. All results reported are
based on two-sided tests. Tests were adjusted for all pairwise
comparisons within a row of each innermost sub-table using the
Bonferroni method of correction. A p < 0.05 was regarded as
statistically significant.
TABLE 3 | OSA severity in terms of respiratory indices.
Symptoms (no = 0, yes = 1) Mean Std. deviation
AHI 0 20.26 17.08
1 18.89 14.19
ODI 0 14.71 15.78
1 15.18 13.92
Mean SaO2 (%) 0 93.92 1.73
1 93.69 2.09
OSA, obstructive sleep apnea; AHI, apnea–hypopnea index; ODI, oxygen
desaturation index.
RESULTS
From 4,118 eligible responders, stratified to represent the Cypriot
population, a cohort of 344 individuals—randomly selected
by SPSS—were enrolled; and 264 subjects (77%) underwent
type III sleep test. According to the diagnostic criteria for
breathing disturbances, 155 had AHI ≥ 5. From these 155
(40 female and 115 male) individuals, 34% had ESS > 10
and 49% AIS ≥ 6. The characteristics of the sleep disturbance
(SDB) group are summarized in Table 1. One or both symptoms
present categorized the individual as symptomatic (Group A, 93
individuals, 60%) and neither major symptom as asymptomatic
(Group B, 62 individuals, 40%).
Males were 72.9% of symptomatic and 74.35 of asymptomatic
OSA patients. Age was 55.78 ± 12.5 in symptomatics and 59.29
± 12.77 in asymptomatics. To ensure the internal validity of our
research, the two groups were tested for confounding factors,
namely, gender, age, and body mass index (BMI). There were no
significant statistical differences (SSDs) between the two groups
(symptomatic–asymptomatic) concerning anthropometrics
(neck, abdomen, and hip circumferences; BMI; age; or gender;
Table 2). The two groups had also no SSD in OSA severity as
concluded by AHI, oxygen desaturation index (ODI), mean
oxygen saturation (SaO2), and comorbidities. Sleep test data are
summarized in Table 3.
Sleep Quality
Symptomatics had statistically significant poorer sleep quality
than asymptomatics (GR-PSQI, 8.41 ± 4.23, vs. 4.88 ± 2.43,
p = 0.000), with no SSD regarding hours in bed (7.14 ± 1.05
vs. 7.24 ± 1.21) and the use of sleep medications (0.45 ± 1.06
vs. 0.18 ± 0.65, comp6). SSDs between OSA patients with and
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FIGURE 2 | Designated effect of categories on PSQI in OSA patients with and without symptoms. PSQI, Pittsburgh Sleep Quality Index; OSA, obstructive sleep apnea.
without symptoms were observed in the subjective perception of
sleep quality (1.61 ± 0.93 vs. 0.81 ± 0.61, p = 0.000, comp1),
sleep latency (1.28 ± 1.05 vs. 0.85 ± 0.87, p = 0.007, comp2),
sleep duration (1.62 ± 0.94 vs. 1.18 ± 0.75, p = 0.001, comp3),
sleep efficiency (1.07 ± 1.25 vs. 0.43 ± 0.80, p = 0.000, comp4),
sleep disturbance (1.6 ± 0.68 vs. 1.07 ± 0.47, p = 0.000, comp5),
and daytime dysfunction (0.79 ± 0.73 vs. 0.38 ± 0.52, p =
0.000, comp7).
The global PSQI score for symptomatics was mainly
determined by sleep disturbance (22.42%), duration of
sleep (20.63%), and subjective sleep quality (19.53%). For
asymptomatics, the decisive factors were primarily duration of
sleep (27.36%) and sleep disturbance (24.62%) (Figure 2). There
was SSD only in the defining contribution of duration of sleep
(p = 0.013) in the configuration of global PSQI between the
two groups (6.20 ± 1.15 for symptomatics vs. 6.66 ± 1.19 for
asymptomatics, p = 0.049), as no SSD was observed in sleep
onset and offset and time in bed.
Finally, when OSA patients with insomnia-like symptoms
were compared with the rest individuals with AHI ≥ 5, all
components of PSQI were SSDs, including the use of sleep
medication. On the contrary, when the sleepy group was
compared with the rest individuals with AHI ≥ 5, there was
no SSD for hours in bed, sleep latency, and use of medication
(Table 4).
Anxiety–Depression–Fatigue
The prevalence and severity of anxiety, depression, and fatigue
were higher in patients with symptoms.
Anxiety was present in 18.1% of symptomatic OSA patients
compared with 2.9% of asymptomatics (p = 0.003), whereas
depression was likely in 12% of symptomatic patients compared
with 2.9% of asymptomatics (p = 0.037). Symptomatics were
more anxious (6.55 ± 4.37 vs. 3.65 ± 3.01, p = 0.000) and
more depressed (6.08 ± 3.81 vs. 3.26 ± 3.28, p = 0.000)
than asymptomatics, according to the HADS score. No SSD
of previous mental illnesses existed between the two groups
(11.1% of symptomatics and 8.7% of asymptomatics). Moreover,
63.4% of symptomatics complained about fatigue vs. 30.3% of
asymptomatics (p = 0.000), with a total score of 4.65 ± 1.61 vs.
3.16± 1.6 (p= 0.000).
We further included the possible confounder PSQI total
score as a variable in our regression models; in this way, we
controlled for the impact of the confounding variable. The
estimated measure of association before and after adjusting for
confounding was examined. The coefficient for symptomatics
dropped more than 10%, when total PSQI was introduced into
the model, meaning that PSQI was a confounding variable that
affected anxiety (p < 0.001, dependent variable) in a causal
relationship, as well as the symptoms (p = 0.027, independent
variable). It was also a confounding variable related with the
depression (p < 0.001) and symptomatic groups (p= 0.011).
Verification
To further support our findings, comparisons were conducted
between a baseline–non-OSA population sample. Sleep quality
was estimated in a control sample of 109 non-SDB subjects with
normal AHI (<5/h). The control sample was not divided into
symptomatics and asymptomatics, as the AHI was the controlled
coefficient. The control sample was summoned after the analysis
of the sleep studies (Figure 1). When compared with the subjects
with abnormal AHI (≥5/h), there was no SSD regarding HADS,
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(mean ± SD, p)
Sleepy OSA
patients
(mean ± SD, p)
Category 1 Subjective sleep
quality
1.85 ± 0.82 1.53 ± 0.95
Category 2 Sleep latency 1.54 ± 1.00 1.00 ± 1.02
Category 3 Duration of
sleep
1.82 ± 0.97 1.62 ± 0.93
Category 4 Sleep efficiency 1.35 ± 1.28 1.04 ± 1.19
Category 5 Sleep
disturbance
1.71 ± 0.63 1.64 ± 0.71
Category 6 Use of sleep
medication
0.53 ± 1.14 0.54 ± 1.15
Category 7 Daytime
dysfunction
0.86 ± 0.70 0.79 ± 0.77
Global PSQI 9.65 ± 3.91 8.15 ± 4.27
OSA, obstructive sleep apnea; PSQI, Pittsburgh Sleep Quality Index.
TABLE 5 | Verification analysis results.
Group No PSQI HADS-Anxiety HADS-Depression
AIS ≥ 6 76 9.65 ± 3.91 7.23 ± 4.34 6.89 ± 3.72
AIS < 6 79 4.77 ± 2.4 3.81 ± 3.19 3.33 ± 3.2
ESS > 10 46 8.15 ± 4.27 6.45 ± 4.54 5.91 ± 3.93
ESS ≤ 10 109 6.15 ± 3.60 4.60 ± 3.66 4.21 ± 3.67
Both symptoms 32 10.42 ± 3.52 7.73 ± 4.54 7.33 ± 3.8
0 or 1 symptom 123 5.86 ± 3.47 4.56 ± 3.66 4.10 ± 3.56
No symptoms 65 4.88 ± 2.43 3.65 ± 3.01 3.26 ± 3.28
Only AIS ≥ 6 44 8.84 ± 4.18 6.71 ± 4.12 6.40 ± 3.64
Both symptoms 32 10.42 ± 3.52 7.73 ± 4.54 7.33 ± 3.80
Only ESS > 10 14 4.40 ± 2.30 4.35 ± 3.77 3.55 ± 2.95
PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale; AIS,
Athens Insomnia Scale; ESS, Epworth Sleepiness Scale.
AIS, PSQI, and all its components. The PSQI score was similar
between the two groups: it was 6.33 ± 3.39 in the control group
vs. 6.75± 3.99 in the SDB group. This reinforces the outcomes of
the study, suggesting the importance of symptoms in subjective
sleep quality. ESS score was significantly higher in AHI≥ 5 group
(6.26 ± 4.16 in the control group vs. 8.31 ± 5.52, p = 0.001).
To further strengthen the clinical relevance of the results of the
study, a separate analysis between subjects with AHI < 15 and
AHI≥ 15 was performed. There was no significant difference for
AIS, ESS, PSQI, depression, and anxiety. An extra proof that AHI
severity is almost irrelevant to the investigated parameters.
Although the AHI or REI metrics are subject to criticism
nowadays, they remain the way we assess patients (20); therefore,
a further classification according to the standard severity of OSA
was conducted. Interestingly, only ESS was significantly higher
between severeOSA and control group (6.26± 4.16 in the control
group vs. 9.47 ± 5.32, p = 0.007), while insomnia, anxiety, and
depression were almost evenly distributed between groups. PSQI
was also insignificantly different, pointing out the importance
of symptoms and not AHI in the quality of sleep. Therefore,
the usual markers of OSA severity do not address efficiently
the sleep quality and psychiatric consequences of the syndrome
if the questionnaires centered on patient-reported symptoms
are not applied. Nevertheless, the small numbers of the four
groups did not allow us to extract solid results between classically
determined severity groups.
The analysis was repeated by using a cutoff of 15/h, which is
the current way to establish the need for treatment. There was
a significant difference only for sleep efficiency (0.74 ± 1.01 in
the control vs. 0.84 ± 1.23, p = 0.005, comp4). Interestingly,
anxiety and depression had no significant difference between the
two groups.
The addition of a control group in the comparison did
not allow us to establish that the symptoms reported,
namely, insomnia and sleepiness, are solely due to the
associated OSA, as these daytime symptoms are expressions
of multiple different conditions and only sleepiness in
severe OSA was statistically different to the control group.
Nevertheless, such an establishment was not the objective
of the study. The comparison with the control group
fortified the importance of symptoms in sleep quality
and psychiatric disturbances, as they differ not because
of AHI but of the symptoms per se. In this regard, the
analysis of classic OSA severity markers did not help in
establishing more firm OSA phenotypes, as the sample
was limited.
Further verification analysis was performed; results are
depicted in Table 5. We compared the patients from the SDB
group according to their response to AIS, ESS, and both. For
patients with or without insomnia, there were strong significant
differences for PSQI (p < 0.000), anxiety (p < 0.000), and
depression (p < 0.000); similar differences were recorded for
patients with or without both symptoms (PSQI, p < 0.000;
anxiety, p < 0.000; and depression, p < 0.000). For patients
with sleepiness compared with patients without sleepiness, there
were also SSDs for PSQI (p < 0.005), anxiety (p < 0.012),
and depression (p < 0.009). A similar sensitivity analysis
for four categories of patients, with solely sleepiness or only
insomnia, both symptoms, or no symptoms, was conducted.
There were significant differences for PSQI between the no
symptoms group and the only insomnia group (p < 0.000)
and the no symptoms group and the both symptoms group
(p < 0.000), but not with the only somnolence group. In
an analogous pattern, there were significant differences for
anxiety between the no symptoms group and the only insomnia
group (p < 0.000) and the no symptoms group and the both
symptoms group (p < 0.000), but not with the only somnolence
group. Similarly, for depression, there were SSDs of the no
symptoms group, respectively, with the only insomnia group
(p < 0.000) and both symptoms group (p < 0.000), but not
the only somnolence group. The results verify the impact of
major sleep symptoms to the psychiatric disturbances, primarily
insomnia, but somnolence cannot be acquitted due to the small
sample groups.
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DISCUSSION
The concept of apnea index was first introduced by Guilleminault
as a metric for sleep apnea syndromes (21). Hypopneas were
officially embraced in the index in a consensus report by
the AASM (22). Subsequently, a persistent argument raised
concerning the cutoff level of desaturation for scoring hypopneas
and the tallying of arousals following respiratory events in the
severity index (respiratory disturbance index) (23). The index
multiplies when lower cutoff points for hypopneas are introduced
and arousals are added in the calculation. AHI is criticized
for correlating weakly with endotype (underlying etiology),
phenotype (symptoms and adverse outcomes), and response to
treatment (23, 24). Rephrasing an elegant editorial by Levy et
al. (25) AHI reflects only a metric in OSA with limited impact
and meaning on a complex entity. That is why novel composite
scores taking into account subjective complaints, comorbidities,
and AHI (26) or integrated scores for multiple constituents of
disease severity (27) gain ground in describing OSA severity. The
widely accepted severity cutoffs 5, 15, and 30 per hour were used
for further analysis even though they are considered invalid for
clinical decisionmaking, as they correlate poorly with symptoms,
comorbidities, and outcomes (28).
It is nowadays broadly recognized that the sole calculation
of the AHI is not sufficient to correctly classify our apneic
patients. Furthermore, excessive daytime hypersomnolence is
not associated with AHI, while insomnia is the dominant
symptom of OSA.Multiple phenotypes with different clinical and
demographic characteristics have been reported, as the syndrome
is more complex by definition. The attempt is to enhance
categorization of OSA patients, link each category to a favorable
treatment option, and ultimately to accomplish precision-based
medicine for OSA patients (24).
Our study intended to address some of the most important
clinical questions and challenges regarding (1) whether clinical
phenotyping of OSA by means of symptom expression,
subjectively measured with ESS and AIS, is related to disease
severity as measured by AHI or other proposed indexes and
(2) whether EDS and/or insomnia-like symptoms in OSA
have adverse effect on PSQI and subsequently or bilaterally
neuropsychiatric disorders (NPDs). According to our data in a
general population of Cyprus, OSA patients reporting insomnia-
like symptoms and/or sleepiness do not represent a more severe
phenotype, by the classic definition of OSA with AHI, but their
subjective sleep quality is compromised, causing a vicious cycle
of anxiety or depression.
The current state of knowledge indicates that the diagnosis
and treatment of OSA, focusing on the number of respiratory
events during sleep, are an oversimplified taxonomy (26). The
complex pathophysiology, the variety of clinical presentation
(e.g., daytime sleepiness, insomnia-like and mood disturbances,
or minimal symptoms), and the relevant comorbidities
(recognized to be highly associated with OSA, e.g., arterial
hypertension) comprise a heterogeneous syndrome.
Recent concepts on differing clinical phenotypes provide
opportunities for a better understanding of the syndrome.
Clustering of symptoms and comorbidities allows discrimination
between clinical subgroups with different characteristics. There
were several attempts to identify clinical subtypes of OSA (8,
9, 11, 12, 29, 30); however, the generalizability of available
data is limited due to methodological differences. Nevertheless,
three generally accepted subgroups are patients with paucity of
symptoms, patients with EDS, and patients with complaints of
insomnia-like sleep disturbance. The conventional description
of a typical OSA patient has focused on symptoms of increased
daytime sleepiness; however, insomnia patients represent the
dominant phenotype in clinical practice. The frequency of
reported insomnia symptoms in different OSA cohorts varies
between 39 and 55% (31). Not < 56% in a cohort were labeled
as an EDS-insomnia or insomnia phenotype (11).
Taking into account the frequent coexistence of symptoms
(EDS-insomnia), we recognized the existence of two clusters
of patients: one with relatively low symptom burden and
another with predominant insomnia-like sleep disturbance
symptoms and/or daytime sleepiness, among newly diagnosed
patients with AHI ≥ 5, in a general population-based study.
These differences in expressing or not nocturnal or diurnal
symptoms may be an add on risk factor for sleep apnea
severity, comorbidities, mental symptoms, and, last but not the
least, sleep quality. Moreover, it is important to know whether
phenotyping the patients for symptoms that are characteristic but
not exclusively attributed to OSA has any clinical importance.
Finally, understanding of the silent asymptomatic cluster of OSA
patients is important in order to re-establish our screening tools
and referral patterns. Simplification to the two most common
specific OSA presentation—asymptomatic vs. symptomatic—
groups is essentially sufficient to assess severity profiles and
collateral consequences.
Symptoms in OSA (EDS, insomnia, depression, fatigue,
etc.) are considered to be influenced by sex, age, and
the presence of other comorbidities (32). In our study,
there were no statistical differences between the two groups
(symptomatic–asymptomatic) in terms of gender, age, or
comorbidities. Actually, there were different outcomes in
the literature concerning EDS and insomnia-like symptoms.
Although sleepiness was linked to cardiovascular morbidity and
mortality outcomes (33), it was not associated with an increase of
prevalence in CVD in a large cohort (34). In another population-
based, cross-sectional study, insomnia prevalence did not differ
between subjects with and without OSA, but moderate-to-severe
OSA subjects reported less insomnia symptoms than subjects
without OSA (35). It is possible that other coexisting sleep
disorders, definition, and assessment of the symptoms and the
studied population also affect the results (9, 36).
PSG is the reference assessment tool for the diagnosis of OSA
(20). Cumulative data demonstrated a weak relationship between
daytime excessive sleepiness and the conventional measures of
OSA severity (e.g., the AHI), and that was also confirmed in our
results. The two groups—symptomatic vs. asymptomatic—had
no differences in terms of AHI, ODI, and mean SaO2 magnitude.
Patients with a high AHI may score low on symptom scales and
vice versa (37). This diversity may be attributed to differences
in individual susceptibility to the systemic effects of OSA. The
clinical definition of OSA based on the combination of AHI
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and daytime symptoms is compromised by the high prevalence
of elevated AHI in the general population and by the poor
correlation of EDS with AHI (38). Type III studies do not include
sleep staging and are expected to give a lower AHI compared
with the calculation based on PSG where periods of wakefulness
during the sleep study are excluded in the calculation of AHI
(39). Underestimation of AHI did not affect our results, as the
dependent factor was symptoms and both groups were subject to
the same bias.
However, our symptomatic group reported poorer sleep
quality on PSQI and complained more often about symptoms
of depression, anxiety, and fatigue than did the asymptomatic
group. The global PSQI score for symptomatics was mainly
determined by sleep disturbance, duration of sleep, and
subjective sleep quality, whereas for asymptomatics, the decisive
factors were primarily duration of sleep and sleep disturbance.
Duration of sleep was less for symptomatics than for
asymptomatics and the best predictor of subjective sleep quality,
but there was no SSD on time in bed. Wake after sleep onset
(WASO) time is not reflected on PSQI calculation, but in our
opinion, it is an important sleep quality factor. In a sleep quality
study in renal transplant patients, the patients with PSQI >
5 were consider as poor sleepers and showed a higher total
medical comorbidity score, poorer mental health, and more
severe anxiety but no difference in depressive symptoms when
compared with the good sleepers group (40). In another sleep
quality study, subjective sleep quality was strongly negative
correlated with depression score, physical symptoms, and trait
anxiety (41), similar to our results. Subjective sleep quality’s
association with sleep onset latency was stronger than with sleep
duration. In a community-dwelling adults study, with mean
PSQI score of 6.3, PSQI and ESS were related poorly with each
other. Participants grouped by either cluster analysis of PSQI
and ESS scores differed from each other on psychological/stress
symptoms, but not on polysomnographic indices. Higher PSQI
scores were associated with greater psychological distress and
larger sleep disturbance on sleep diaries. Finally, the PSQI was
more closely related to psychological symptom ratings and sleep
diary measures than the ESS (42).
Poor sleep quality has a major long-term impact on mental
and physical health. Our study identified a cause-and-effect
relationship between PSQI and symptoms of anxiety and
depression. PSQI had a causal relation to the symptoms,
especially insomnia; and symptoms’ expression correlated
with poor sleep quality and separately with anxiety and
depression. There is growing evidence for an increased
frequency of OSA in a variety of NPDs, including stroke,
neurodegenerative/muscular disorders, major depression, and
post-traumatic stress disorder (43, 44). Several studies suggest
that OSA not only may be frequent but also represents an
independent risk factor for the subsequent development of
NPDs, such as depression (45).
AHI was not related to the risk for hospitalization for
depression in a study by Kendzerska et al. (46), and a causal
link between OSA and severe depression was not supported.
Nevertheless, higher depressive symptoms were reported in
OSA patients (47), almost doubled in prevalence for the OSA
group compared with the no-OSA group in a population-
based study (48). About 17% of OSA patients had a major
depressive disorder in a large community sample (49) and up
to 40% in clinical samples (47, 50). Moreover, a large general
population study found an association between EDS, rather than
OSA per se, and depression (51) and introduced symptoms
in the equation. Association between OSA and depressive
symptoms is questioned, but findings indicate that depression is a
consequence of OSA (52, 53), and major sleep-related symptoms
may be the mediators in this relation. Correction for confounders
for depression like obesity, young age, female sex, and hypnotic
medication use was not applied, as there were no SSDs between
groups for these characteristics.
AHI proved once more a convenient metric but with limited
clinical implications. The results of our study suggest that
patients with depression should be routinely questioned for
symptoms of insomnia and/or sleepiness, as further assessment
and treatment for sleep-disordered breathing may mitigate
depressive symptoms. The effects of OSA treatment in depression
and anxiety especially in the symptomatic phenotype have to
be assessed.
The major strength of our research is the validity of our
findings, which is documented by the large representative
population-based sample size and by the high response rate.
This allows us to generalize the results, enabling extrapolation
of findings to the original population. Moreover, we included
all adult age groups, from 18+ to 80+ years old. Another
major advantage of our study is the community-based, randomly
selected sample that is optimal for epidemiological studies. As
subjects were recruited from the community and not from
clinical sleep canters, there is no referral bias, causing a
spurious association of OSA with risk of comorbidities. The
study identified a sleep lab-naive sample; and as OSA patients
were excluded from the study, a better assessment of the
natural history of untreated OSA is possible. A strength of
our study is also the application of common questionnaires
and simple phenotyping methodology across a population-based
sample. Our study did not include all possible symptoms and
comorbidities nor complicated phenotyping but only focused on
major sleep symptoms that may occur in patients with OSA.
This simplification in two groups minimizes the need for a larger
sample to support SSD. Moreover, most of the previous studies
included patients with moderate-to-severe OSA, and the clusters
found may not be generalizable to patients with milder OSA.
An important feature of our study is that all individuals with
AHI ≥ 5 were introduced in the study. Reflecting the established
demographic risk factors for OSA, the cohort was generally
middle-aged, moderately obese, and predominantly male.
Limitations must also be acknowledged. A self-reported
questionnaire concerning the history of comorbid diseases was
assembled, but no medical assessment was provided in those
with a negative history in order to identify non-diagnosed
comorbidities. Another limitation is the absence of a psychiatric
revision of the participants according to their self-reported
mental questionnaires. Any differences with previous reports
may be attributed to cultural or regional differences in symptom
reporting (54, 55) or referral strategies and access to care,
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together with existing known variation in OSA etiology across
ethnic groups (56–60).
As Young stated, there is more to be done in the quantification
of the adverse health consequences of OSA in order to define
the overall social burden (61). Experts recognizing the poor
correlation between AHI and daytime symptoms, as well the
multivariate expression of the syndrome, advised a revision of
the diagnostic criteria and severity thresholds for OSA, taking
into consideration the different clinical and pathophysiological
phenotypes and relevant comorbidities (26). To conclude,
identification of two distinct groups according to the expressed
daytime symptoms, symptomatics and asymptomatics, requires
future surveys concerning diagnostic screening, consequences,
and effective treatments.
CONCLUSION
According to our study, OSA patients reporting insomnia and
or sleepiness do not represent a more severe phenotype as to
the classic taxonomy of syndrome’s gravity categorized by the
number of apneas and hypopneas per hour of sleep. Neither
do symptomatics report a greater number of comorbidities.
Nevertheless, symptomatics express poor sleep quality and mood
disturbances significantly different from asymptomatics. The
explanation given is that their sleep quality is compromised,
causing a vicious cycle of anxiety or depression.
The results of the study indicate that the severity of the sleep
respiratory pathology represented by AHI is inadequate. Even
with the addition of oxygenation indices for the cardiovascular
manifestations of the syndrome as we demonstrated in a previous
study (62) and the daytime symptoms as we proposed in this
study, one is uncertain to suggest a novel classification, as there
are more elements missing. Nevertheless, objective assessment
using symptom questionnaires is in our opinion essential and
should be compulsory, as they illuminate the sleep quality aspect
and predisposition for psychic imbalance.
This study contributes to the understanding of the impact
of EDS and insomnia in OSA. According to our results, we
ought to reconsider our screening techniques, customized to the
patient’s complaints, probably with the utility of sleep quality
questionnaires and screening tools for NPDs. Moreover, it
will be desirable to validate clinical assessment methods that
correctly classify a new OSA patient. This understanding could
enhance personalized treatment approaches in OSA patients.
Finally, a new conceptual framework to evaluate disease severity
of OSA may be developed. The diagnostic workup should
incorporate this multifactorial approach and define severity,
not only considering AHI but also including EDS, NPDs (e.g.,
cognitive impairment and depression), related sleep disturbances
(e.g., insomnia), consequences, and prognoses.
A confirmation of the current findings in longitudinal studies
would be needed to more precisely evaluate the value of defining
clinical presentation phenotype.
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